46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
49 citations
,
August 2018 in “International Journal of Dermatology” In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.
9 citations
,
August 2018 in “JAAD Case Reports” This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.
53 citations
,
July 2018 in “Drug design, development and therapy” This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.
20 citations
,
January 2018 in “Expert opinion on emerging drugs” This review discusses the potential of Janus Kinase inhibitors for treating alopecia areata and other forms of alopecia, highlighting the need for further research on their long-term safety and optimal formulation.
102 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.
20 citations
,
November 2017 in “JAAD case reports” This case report describes a patient with psoriasis, vitiligo, and alopecia areata who showed significant improvement in all conditions after treatment with ustekinumab, suggesting potential benefits of IL-12/23 blockade for these autoimmune diseases.
27 citations
,
September 2017 in “Archives of Dermatological Research” In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” In this study, the first case of a persistent curly hair phenotype was reported with nivolumab treatment in a patient with metastatic squamous cell lung cancer.
30 citations
,
October 2016 in “Current research in translational medicine” This essay reviews the role of human scalp hair follicles in the "brain-skin connection," highlighting their dual function as targets and sources of neurohormones, without reporting new experimental results.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
67 citations
,
July 2016 in “Reviews in Endocrine and Metabolic Disorders” This review discusses the complex relationship between stress and various skin conditions, highlighting the role of the skin in the stress response and the brain-skin communication pathways, but reports no new research findings.
70 citations
,
April 2016 in “Experimental Dermatology” In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.
41 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.
159 citations
,
October 2015 in “Science Advances” This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.
62 citations
,
June 2015 in “The Journal of Dermatology” This study found that patients with alopecia areata had higher levels of Th17 cells and lower levels of regulatory T cells compared to healthy controls, suggesting an immune imbalance in these patients.
42 citations
,
March 2015 in “Anais Brasileiros de Dermatologia” This study reports two cases of alopecia associated with anti-TNF therapy, highlighting a new entity combining features of alopecia areata and psoriatic alopecia.
45 citations
,
December 2014 in “Journal of the European Academy of Dermatology and Venereology” This study found that plasmacytoid dendritic cells are central to the pathogenesis of alopecia areata, suggesting they may help differentiate it from trichotillomania and androgenetic alopecia.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
22 citations
,
January 2014 in “Journal of Interferon & Cytokine Research” In this study, researchers found that specific IL18 genetic variants may be linked to increased susceptibility to alopecia areata in a Korean population.
12 citations
,
January 2014 in “Annals of Dermatology” This study found an association between hydroxyl radical-modified SOD and alopecia areata, suggesting these modifications may lead to antibody induction in the condition.
23 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” This study highlights rapid advances in alopecia areata treatment following the identification of genetic variants associated with increased disease risk, suggesting potential for precision medicine approaches.
71 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This review discusses various treatments for alopecia areata, highlighting their limitations and individualized approach, and reports no new clinical results.
110 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This article reviews current understanding of alopecia areata, its genetic and immune factors, and discusses ongoing research and treatment development, without presenting new experimental results.
37 citations
,
September 2012 in “Archives of dermatology” Diphencyprone can help some children with alopecia areata regrow hair, but it often causes side effects.
421 citations
,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
717 citations
,
June 2010 in “Nature” This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.
52 citations
,
March 2010 in “British Journal of Dermatology” This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.
45 citations
,
January 2010 in “International journal of trichology” This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.
159 citations
,
November 2007 in “American Journal of Pathology” In this study, researchers found that substance P triggered premature catagen development and immune changes in human scalp hair follicles, providing a possible biological link between stress and hair loss conditions like telogen effluvium and alopecia areata.
286 citations
,
August 2007 in “Journal of Clinical Investigation” This review examines the interplay of genetics and neuroimmunology in alopecia areata, highlighting its potential to inform broader autoimmunity research, but reports no new findings.
61 citations
,
February 2003 in “Experimental Dermatology” This study found that increasing dietary soy oil content reduced alopecia areata development in C3H/HeJ mice, though genistein injection showed no significant effect.
86 citations
,
December 2002 in “Tissue Antigens” In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.
114 citations
,
August 2002 in “Journal of Investigative Dermatology” Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.
131 citations
,
November 1998 in “The journal of investigative dermatology/Journal of investigative dermatology” This study observed that alopecia areata can be induced and serially transferred in C3H/HeJ mice using skin grafts, providing a useful model for studying the disease in humans.
87 citations
,
October 1997 in “JAMA” This case series suggests a possible, though likely very rare, association between vaccinations and hair loss, calling for further research in more defined populations.
91 citations
,
March 1996 in “Archives of Dermatological Research” This study concluded that cytokines and growth factors significantly regulate hair growth in vitro, with some completely inhibiting growth, such as EGF and TNFα.